10 Best Cheap Stocks to Buy for Beginners
Goldman Sachs’ Ben Snider told CNBC that markets are focused on near-term visible earnings; he expects S&P 500 earnings growth of 24% this year and 13% next year, with AI infrastructure beneficiaries driving about half. The article screens for stocks with forward P/E <15 and high hedge-fund popularity (Insider Monkey, Q1 2026). It lists Toyota (sales down 3.1% YoY in April) and Novartis (Cosentyx Phase 3 REPLENISH PMR data).
Hydrogen motorsports demo is a catalyst narrative, but the bigger near-term risk signal is weaker global vehicle sales.
Toyota announced first public drives of its liquid hydrogen-fuelled TR LH2 prototype ahead of Le Mans, plus Reuters-cited April sales weakness in China/Middle East.
Likely modest, two-sided reaction: upside on hydrogen tech visibility; downside if investors focus on slowing sales momentum.
Background
The piece is a beginner-oriented “cheap stocks” list using a forward P/E <15 screen and hedge-fund popularity, with company-specific catalysts for TM and NVS in the excerpts provided.
Why it matters
TM has both a technology visibility catalyst (hydrogen prototype demo) and a demand headwind (April sales decline in key regions). NVS has a clear clinical readout catalyst (Phase III REPLENISH) that can affect expectations for Cosentyx’s PMR positioning.
Market relevance
This article is not a market-mover headline, but it contains two company-specific, time-stamped catalysts (auto hydrogen demo + pharma trial data) that can drive short-term sentiment and positioning.
Market effects
Semis/AI infrastructure are referenced as the earnings-growth engine, but the actionable company-specific catalysts here are auto hydrogen tech and pharma clinical data.
Toyota’s sales weakness is tied to China and the Middle East, which can influence regional auto demand sentiment.
Hydrogen motorsports development is globally relevant for alternative-fuel narratives; PMR trial data is globally relevant for immunology/biopharma competitive positioning.
Alternative perspectives
The “cheap stocks” framing is largely screening/positioning; Toyota’s hydrogen demo may not translate into near-term financial impact, and Novartis trial success may already be partially anticipated by the market.
For TM, investors may discount motorsports prototypes versus actual commercial hydrogen adoption timelines; for NVS, the market will still focus on regulatory pathway, comparator strength versus standards of care, and uptake dynamics beyond week-52 efficacy.
Key entities
- product_eventToyota Racing TR LH2 Racing Prototype
First public demonstration drives ahead of Le Mans 24 Hours, intended to advance hydrogen technology in motorsports.
- clinical_trialCosentyx REPLENISH Phase III (PMR)
Phase III data showing sustained remission and steroid sparing through week 52 with no new safety signals.
